Chiropractors in Anna, OH Accepting Medicare
4 Chiropractors found. Showing 1 - 4
 Billing Chiropractic Inc. Chiropractor Medicare: Medicare Enrolled Practice Location: 121 Shue Dr, Anna, OH 45302 Phone: 937-691-2030 Fax: 937-691-2035 |
Baker Chiropractic, Llc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 515 E Main St, Suite A, Anna, OH 45302 Phone: 937-639-2060 Fax: 937-639-2061 |
 Dr. Adam C Baker, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 515 E Main St, Suite A, Anna, OH 45302 Phone: 937-639-2060 Fax: 937-639-2061 |
Dr. Derek Billing, DC Chiropractor Medicare: May Accept Medicare Assignments Practice Location: 121 Shue Dr, Anna, OH 45302 Phone: 937-691-2030 Fax: 937-691-2035 |
News Archive
Organogenesis to showcase study results of Apligraf product at SAWC / WHS 2010
Organogenesis, Inc. will have a substantial presence at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society being held April 17-20 in Orlando, FL. Results from several clinical and scientific studies will be presented which will further the understanding of Organogenesis' bilayered living cellular construct technology.
Merck, sanofi-aventis enter global cancer research and development agreement
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that Merck, has signed a worldwide research and development agreement with sanofi-aventis U.S. Inc., under which Merck Serono and sanofi-aventis U.S. Inc. will collaboratively investigate novel experimental combinations of agents that could block specific pathways in cancer cells. This collaboration could deliver novel targeted oncology treatments with high therapeutic potential.
Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010
In a new study of treatment-experienced HIV-1-infected adults with no PREZISTA® (darunavir) resistance-associated mutations (RAMs), 72 percent of patients in the PREZISTA/ritonavir (r) (800/100 mg) once-daily arm achieved undetectable viral loads (<50 copies/mL) compared with 71 percent of patients in the PREZISTA/r (600/100 mg) twice-daily arm. The study met its primary objective of non-inferiority. These data from the Phase 3b ODIN study were presented today at CROI 2010, the 17th Conference on Retroviruses and Opportunistic Infections, in San Francisco.
Beckman Coulter Genomics Introduces a Scalable RNA-seq service line for processing intact and degraded RNA samples
This fully automated sample preparation pipeline delivers consistent results run after run, reducing user variability and bias and allows processing of a large amount of samples with reduced turnaround time relative to manual library construction.
Memorial Sloan-Kettering Cancer Center awards $50,000 to three young investigators
Three young investigators who have taken significant steps toward advancing the understanding of cancer will be the recipients of this year's Paul Marks Prize for Cancer Research, a prize awarded biennially since 2001 to scientists under the age of forty-six by Memorial Sloan-Kettering Cancer Center.
› Verified 3 days ago